Related Experiment Videos
Role of an anti-epidermal growth factor receptor in treating cancer
1ImClone Systems Incorporated, New York, NY, USA.
Abstract:
Recent technological advances, together with the discovery of the important role many growth factors play in modulating cell proliferation and differentiation, have led to the development of novel therapeutic agents for the treatment of cancer. In particular, advances in hybridoma technology and molecular engineering have permitted the development of humanized or chimeric monoclonal antibodies capable of interfering with growth factor signaling pathways. One promising target of interest is the epidermal growth factor receptor (EGFr), which is activated by the ligands EGF and TGF-alpha. This ligand receptor interaction plays a crucial role in the growth and survival of many human cancers. A chimeric (human/mouse) monoclonal antibody p6tuximab (IMC-C225) targets the EGFr and has potential clinical value as an anticancer agent.
Insights
Novel chimeric monoclonal antibodies target the epidermal growth factor receptor (EGFr) to treat cancer. P6tuximab (IMC-C225) shows potential as an anticancer agent by interfering with EGFr signaling pathways crucial for tumor growth.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Growth factors significantly influence cancer cell proliferation and differentiation.
- Technological advancements enable the development of targeted cancer therapies.
- Epidermal growth factor receptor (EGFr) signaling is vital for many human cancers' growth and survival.
Purpose of the Study:
- To explore novel therapeutic agents for cancer treatment.
- To investigate the potential of monoclonal antibodies targeting growth factor signaling pathways.
- To evaluate p6tuximab (IMC-C225) as a potential anticancer agent targeting EGFr.
Main Methods:
- Utilizing hybridoma technology and molecular engineering.
- Developing humanized or chimeric monoclonal antibodies.
- Targeting the epidermal growth factor receptor (EGFr) pathway.
Main Results:
- Monoclonal antibodies can interfere with growth factor signaling.
- P6tuximab (IMC-C225) is a chimeric monoclonal antibody targeting EGFr.
- EGFr is activated by ligands like EGF and TGF-alpha.
Conclusions:
- Targeting EGFr with monoclonal antibodies is a promising cancer treatment strategy.
- P6tuximab (IMC-C225) demonstrates potential clinical value in cancer therapy.
- Interference with EGFr signaling can impact cancer cell growth and survival.